Zoledronic Acid Dosing Interval for Metastatic Cancer —Reply

In Reply Dr Tanimoto and colleagues raise a valid point about the apparent survival advantage of monthly zoledronic acid, but not other bisphosphonates, when added to conventional treatment for patients with untreated multiple myeloma. The CALGB 70604 (Alliance) trial was not restricted to untreated vs previously treated patients with multiple myeloma nor was it powered to address a survival end point. Hence, given the potential survival benefit of zoledronic acid in first-line treatment of multiple myeloma, clinicians and patients with multiple myeloma may want to have a more focused discussion concerning the optimal dosing interval of zoledronic acid.
Source: JAMA - Category: Journals (General) Source Type: research